![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
![[thumbnail of Supplementary Information]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Information)
697kB |
| Item Type: | Article |
|---|---|
| Title: | Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma |
| Creators Name: | Fuchs, M., Jacob, A.S., Kaul, H., Kobe, C., Kuhnert, G., Pabst, T., Greil, R., Bröckelmann, P.J., Topp, M.S., Just, M., Hertenstein, B., Soekler, M., Vogelhuber, M., Zijlstra, J.M., Keller, U.B., Krause, S.W., Dührsen, U., Meissner, J., Viardot, A., Eich, H.T., Baues, C., Diehl, V., Rosenwald, A., Buehnen, I., von Tresckow, B., Dietlein, M., Borchmann, P., Engert, A. and Eichenauer, D.A. |
| Abstract: | The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in patients with early-stage favorable Hodgkin lymphoma (HL). This analysis reports long-term outcomes. Overall, 1150 patients aged 18-75 years with newly diagnosed early-stage favorable HL were randomized between standard combined-modality treatment (CMT) (2x ABVD followed by PET/CT [PET-2] and 20 Gy involved-field RT) and PET-2-guided treatment omitting RT in case of PET-2 negativity (Deauville score [DS] < 3). The study aimed at excluding inferiority of PET-2-guided treatment and assessing the prognostic impact of PET-2 in patients receiving CMT. At a median follow-up of 64 months, PET-2-negative patients had a 5-year progression-free survival (PFS) of 94.2% after CMT (n = 328) and 86.7% after ABVD alone (n = 300; HR = 2.05 [1.20-3.51]; p = 0.0072). 5-year OS was 98.3% and 98.8%, respectively (p = 0.14); 4/12 documented deaths were caused by second primary malignancies and only one by HL. Among patients assigned to CMT, 5-year PFS was better in PET-2-negative (n = 353; 94.0%) than in PET-2-positive patients (n = 340; 90.3%; p = 0.012). The difference was more pronounced when using DS4 as cut-off (DS 1-3: n = 571; 94.0% vs. DS ≥ 4: n = 122; 83.6%; p < 0.0001). Taken together, CMT should be considered standard treatment for early-stage favorable HL irrespective of the PET-2-result. |
| Keywords: | Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Dacarbazine, Doxorubicin, Follow-Up Studies, Hodgkin Disease, Neoplasm Staging, Positron Emission Tomography Computed Tomography, Vinblastine |
| Source: | Leukemia |
| ISSN: | 0887-6924 |
| Publisher: | Nature Publishing Group |
| Volume: | 38 |
| Number: | 1 |
| Page Range: | 160-167 |
| Date: | January 2024 |
| Official Publication: | https://doi.org/10.1038/s41375-023-02064-y |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
